课题基金 / 基金详情

Cancer Immunology Training Program

Cancer Immunology Training Program
癌症免疫学培训计划
批准号:
10670409
负责人:
Robert J Binder
金额:
$51.87万
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
未结题
起止时间:
1999-07-01 至 2027-06-30

项目摘要

项目成果

Robert J Binder的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY Interest in cancer immunology has never been more intense. Breakthrough observations with inhibitory receptor blockade, combined with ground breaking advances in the use of chimeric antigen receptor (CAR)-modified T cell adoptive therapies have highlighted the critical need to further basic and translation research in cancer immunology. While the pipeline of potential immunotherapeutic targets is growing, the pipeline of future cancer immunologists is limited, in part due to significant demand in industry and academia. There is a critical need for training programs that optimally prepare the next generation of cancer immunologists. Surprisingly, our Cancer Immunology Training Program (CITP) at the University of Pittsburgh School of Medicine (UPSOM) is one of only six NCI-supported T32s nationwide that focus entirely on cancer immunology. This makes our program unique and essential. CITP, which has 5 pre- and 3 post-doctoral slots, is in its 20th year and we are seeking support for the next five years. The goals of the CITP are to provide graduate students, fellows and physician scientists with courses, research projects, exceptional environment and resources, and highly-qualified mentors that will allow them to: (1) make a significant contribution to one of five areas of research focus covered by this training program: (a) Inhibitory Mechanisms in the Tumor Microenvironment (TME), (b) Adaptive Immunity and Cellular Interactions within the TME, (c) Innate, Environmental and Metabolic Modulation, (d) Promoting Immune Responses to Tumors: Cell-Based Therapies & Vaccines, and (e) Systems Cancer Immunology; (2) gain a clear understanding of the cellular and molecular mechanisms relevant to cancer immunology; (3) obtain a practical understanding of the immunology of human cancer; (4) gain a clear conceptual understanding of all areas that impact cancer immunology; and (5) develop critical career skills and managerial ability. Building thoughtfully on what is a proven training program, we have made several enhancements, such as increasing the cancer immunology-focus of our faculty (25 total). UPSOM and HCC have and continue to make an unprecedented investment in cancer immunology. The training program exploits particular strengths at UPSOM, including an exceptional NCI Comprehensive Cancer Center, a strong immuno-centric translational research base, an outstanding Immunology Department that underpins strong basic research, and our graduate research program (PMI). UPSOM has implemented effective programs to ensure outstanding training, with emphasis on increasing the recruitment and retention of women and URMs. Our applicant pool is exceptional due to the success of our PMI and MSTP graduate programs, highly sought-after clinical fellowships, and outstanding mentor pool. Over the last 5 years, CITP has enrolled 24 trainees (Pre – 15; Post – 9), of which 13 were women (54%) and 3 were URM (12.5%). Lastly, our trainees have been extremely successful in obtaining extramural/competitive fellowships (14 total [58%]: F99/K00 [1], F32 [3], F31 [4], F30 [3], Damon-Runyon [1], St. Baldrick's [1], Hartwell [1]). We are excited and eager to train the next generation of cancer immunologists.
期刊论文(71)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1002/eji.200939667
发表时间: 2010-02
期刊: EUROPEAN JOURNAL OF IMMUNOLOGY
影响因子: 5.4
作者: [Lipscomb, Michael W., Taylor, Jennifer L., Goldbach, Cristina J., Watkins, Simon C., Wesa, Amy K., Storkus, Walter J.]
通讯作者: Storkus, Walter J.
Immune-checkpoint blockade and active immunotherapy for glioma.
免疫检查点阻滞和神经胶质瘤的主动免疫疗法。
DOI: 10.3390/cancers5041379
发表时间: 2013-11-01
期刊: Cancers
影响因子: 5.2
作者: [Ahn BJ, Pollack IF, Okada H]
通讯作者: Okada H
DOI: 10.1158/0008-5472.can-10-1369
发表时间: 2010-11-15
期刊: Cancer research
影响因子: 11.2
作者: [Pardee AD, McCurry D, Alber S, Hu P, Epstein AL, Storkus WJ]
通讯作者: Storkus WJ
DOI: 10.4049/jimmunol.1401608
发表时间: 2014-11-01
期刊: Journal of immunology (Baltimore, Md. : 1950)
影响因子: --
作者: [Park KS, Bayles I, Szlachta-McGinn A, Paul J, Boiko J, Santos P, Liu J, Wang Z, Borghesi L, Milcarek C]
通讯作者: Milcarek C
40
    CD91 and cancer immunosurveillance
    CD91 and cancer immunosurveillance
    CD91 and cancer immunosurveillance
    Heat shock protein gp96 and Treg responses
    海外基金